Riskgaming

Qasar Younis, co-founder of Applied Intuition, shares how they achieved a $6 billion valuation and a partnership with Porsche by applying Silicon Valley's startup practices to the automotive industry. They discuss the importance of culture, recruitment strategies, open-source technology, Tesla's impact on the industry, and the role of VCs in startup growth.

The podcast discusses the shift in tech from Star Trek's utopia to Douglas Adams' absurdism, exploring design fiction, AI, and creativity. They touch on the influence of sci-fi, management cybernetics, and democratizing programming, highlighting the evolving nature of technology and the importance of imagination in innovation.

We’ve known for decades that one of the key mechanisms of biology — and of life itself — is the binding of molecules to proteins. Once bound, proteins change shape and thus their function, allowing our bodies to adapt and change their molecular machinery as needed for survival. The challenge that remains unsolved is to predict — across billions of potential proteins and a similar number of molecules — how those proteins change and how they might interact with each other. The fervent hope of many scientists and entrepreneurs is that artificial intelligence coupled with experimental and synthetic datasets, may finally unlock this critical piece of the biological puzzle, ushering in a new wave of therapeutics. My guest today is one of those science entrepreneurs, Laksh Aithani, the co-founder and CEO of Charm Therapeutics. He’s made cancer the focus of his work, and through Charm and his team, is building expansive datasets to develop AI models that can predict the 3D shape of proteins. Alongside host Danny Crichton and my Lux colleague Tess van Stekelenburg, we explore protein folding’s past, present and future, the utility and risks of synthetic data in biological research, how much money and time we might expect for future drug discovery, what individualized medicine might look like decades from now, and how new grads can get into the field as the century of biology kicks off. Produced by ⁠⁠⁠⁠⁠⁠⁠⁠Christopher Gates⁠⁠⁠⁠⁠⁠⁠⁠ Music by ⁠⁠⁠⁠⁠⁠⁠⁠George Ko⁠⁠⁠⁠⁠⁠⁠⁠

Margaret Mead, an influential anthropologist, delves into the realms of psychedelic research, connecting scientific communities interested in exploring computer science, neurology, and consciousness. Joined by science professor Benjamin Breen and Lux Capital's Sam Arbesman, they explore Mead's work and the historical context of psychedelics post-World War II, shedding light on indigenous traditions, societal transformations, and the intersection of science, social history, and maps.

Ever since the invention of CRISPR technology about a decade ago, biologists have gained increasing power to discover new DNA sequences, cut and mash them up, and then print them in ever larger volumes through biomanufacturers. That freedom and openness is the opening to a long-awaited Century of Bio, with scientists bullish on the potential to discover cures to long-resistant diseases. On the tails side of the coin though, there are fears that the open nature of these tools afford a rebel scientist the means of inventing and distributing well-known or completely novel pathogens that could threaten the lives of millions. It’s not the premise for a bad Hollywood B-movie, but a top security threat that experts at the White House and in the intelligence and defense communities are rapidly trying to solve. Today, I have Kevin Flyangolts of Aclid joining us. Aclid is using artificial intelligence to identify what new sequences of DNA might do, scaling up screening efforts that might allow biomanufacturers the ability to verify their customers’ intentions in a more thoughtful and comprehensive way. Kevin and host Danny Crichton talk about the recent history of bio, the rise of biohacking, the differences between bioweapons, cyberweapons and financial crimes, why we need new approaches to biosecurity, whether executive, legislative or industry approaches might work best, and whether designer bioweapons are as dangerous as many are making them out to be.Finally, a note: in line with the launch of our first riskgaming scenario on the Lux Capital website, Hampton at the Cross-Roads, we have officially condensed the “Securities” podcast name into just “Riskgaming,” which I think captures in one word the risks and opportunities that come from science, technology, finance and the human condition. Same show, more focused name and a great future. Produced by ⁠⁠⁠⁠⁠⁠⁠⁠Christopher Gates⁠⁠⁠⁠⁠⁠⁠⁠ Music by ⁠⁠⁠⁠⁠⁠⁠⁠George Ko⁠⁠⁠⁠⁠⁠⁠⁠ & Suno

Josh Wolfe, Lux co-founder, discusses the new theme of 'maintenance' as a growth industry. They explore the value of maintaining existing systems amidst entropy, the significance of maintenance in deep tech investments, financial implications of catastrophic events, the importance of continuous energy input in systems, and the vital role of maintainers in upholding essential systems.

This week’s solar eclipse captured the imaginations of millions of Americans throughout an arc across the continent. One of those entranced was Sam Arbesman, Lux’s scientist-in-residence and a local of Cleveland, which sat in the full zone of totality. Sam also happened to live in Kansas City during the 2017 eclipse, so he has (accidentally) eclipsed-chased in his choices of residence. Briefly, Sam and host Danny Crichton talk about the eclipse, the mesmerizing impact of science, and the unique community that comes together in cities lying in the darkness. Lux is “light” in Latin, and so what happens when darkness descends across the Earth? Surprisingly, something magical and optimistic, showing how science and mathematics has the ability to transmute our passions into something great. Produced by ⁠⁠⁠⁠⁠⁠⁠⁠Christopher Gates⁠⁠⁠⁠⁠⁠⁠⁠ Music by ⁠⁠⁠⁠⁠⁠⁠⁠George Ko⁠⁠⁠⁠⁠⁠⁠⁠

During a recent interview, Nvidia CEO Jensen Huang emphasized his interest in how Nvidia’s AI processing chips could transform the science of life. He noted that this science, when properly understood, could evolve into a new form of engineering. Currently though, we lack the knowledge of how the extreme complexity of biology works, nor do we have models — namely AI models — to process that complexity. We may not have a perfect understanding of biology, but our toolset has expanded dramatically over the past ten years. Now, with the combination of data, biology and AI, we’re seeing the early signs of a golden era of biological progress, with large-language models that are able to predict everything from protein folding to increasingly, protein function. Entire spaces of our map are being discovered and filled in, and that is leading to some bullish scientists and investors to call the period we are living in the century of biology. But much remains to be done, and that’s the topic of our episode today. Host Danny Crichton is joined by Lux Capital’s bio investor Tess van Stekelenburg. Tess and Danny talk about Nvidia’s recent forays into biology as well as the new foundational model Evo from the Arc Institute. They then look at what new datasets are entering biology and where the gaps remain in our global quest to engineer life. Finally, they’ll project forward on where evolution might be taking us in the future once unshackled by nature. Produced by ⁠⁠⁠⁠⁠⁠⁠⁠Christopher Gates⁠⁠⁠⁠⁠⁠⁠⁠ Music by ⁠⁠⁠⁠⁠⁠⁠⁠George Ko⁠⁠⁠⁠⁠⁠⁠⁠

Astrobiology has seen major revolutions in the past three decades, challenging old perceptions. The guest, Adam Frank, talks about identifying biosignatures and technosignatures of life. The Habitable Worlds Observatory could be the first satellite dedicated to the search for life. The podcast also discusses the impact of AI on the search for extraterrestrial life and the potential discoveries in astrobiology in the coming years.

Humans are enamored by a good story. The world overloads our mammalian senses, and so we seek any simplifying structure to narrate what we are witnessing and make it more accessible for processing. That simplification doesn’t just reduce the complexity of the world, but also makes it difficult to see the extent by which luck drives the successes of our geniuses — and the failures of others. From scientific discoveries and power-law venture returns to legislative breakthroughs and decisions during war, the world is, essentially, chaos. That might trigger a bout of deep existentialism for many of us, but for Brian Klaas, the hope is that confronting the stochastic nature of the world can lead to better governance and progress. In his new book Fluke, Klaas argues that we need to upend the simplistic statistical analyses and modeling that are common across social science and other domains and replace it with one that can encompass a theory of flukes. That means understanding timing, path dependency, and how the world is a complex system that is far more of a continuous variable than a binary one. With Lux’s scientist-in-residence Sam Arbesman and host Danny Crichton, we all talk about how chaos rules our lives; how a better understanding of complexity can improve investments, science, and life; Darwin’s luck of publishing his research on natural selection; the dangers of the human penchant for finding narrative; the random luck of our life experiences; and why understanding flukes can be a counterpoint to the ideas of moneyball. Produced by ⁠⁠⁠⁠⁠⁠⁠⁠Christopher Gates⁠⁠⁠⁠⁠⁠⁠⁠ Music by ⁠⁠⁠⁠⁠⁠⁠⁠George Ko⁠⁠⁠⁠⁠⁠⁠⁠ & Suno